Key result
China's ischemic heart disease prevalence is projected to rise ~2.3-fold by 2030, reaching 154 million patients.
Why the study?
Ischemic heart disease has become a serious public health threat, prompting the need to predict its future prevalence and economic burden in China.
The prevalence and economic burden of ischemic heart disease in China are projected to increase substantially, reaching 154 million patients and a $512 billion economic burden by 2030, underscoring the urgent need for large-scale preventative and lifestyle interventions.
May highlight need for prevention planning in China; leaves open whether interventions can alter projected ischemic heart disease growth.
Ischemic heart disease (IHD), characterized by myocardial damage from altered coronary circulation, has become a serious threat to the public health of the population. We aimed to predict the future prevalence of IHD and estimate its economic burden in China. Data on the number of patients with IHD in China were derived from the Global Burden of Disease. Long Short-Term Memory network was trained on data from 1990 to 2015, and validated using data to predict the future prevalence of IHD from 2022 to 2030. We used the bottom-up and human capital approach to estimate the direct and indirect economic burden of IHD, respectively. The model demonstrated a strong fit on the training set, and the results of RMSE (212,356.03), MAE (163,366.30), MAPE (0.57%) and R2 (99.95%) showed that the model fitted well. On the testing set, the results of RMSE (364,393.64), MAE (321,570.00), MAPE (0.54%) and R2 (97.96%) showed that the model predicted well. From 2022 to 2030, the number of patients with IHD is projected to increase from approximately 66 million to 154 million. From 2022 to 2030, the total economic burden of IHD would be approximately $220 billion, $233 billion, $247 billion, $265 billion, $288 billion, $318 billion, $359 billion, $418 billion and $512 billion, respectively. The prevalence and economic burden with IHD in China are projected to increase substantially in the future. These findings underscore the urgent need for collaborative efforts among the state, society, and the public in the prevention and control of IHD to reduce the economic burden.
No takes yet. Share an insight, caveat, or question.
Teng et al. (2025) studied Ischemic heart disease (n=63,331,312). Time (2022-2030 projection) vs. Historical data (1990-2021) was evaluated on Future prevalence of ischemic heart disease and its economic burden. From 2022 to 2030, the number of patients with ischemic heart disease in China is projected to increase from 66 million to 154 million, with the total economic burden rising to $512 billion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: